Details for 2020807558

Up to date per 01.04.2026

Actions

Title / Product Name

VERFAHREN ZUR BEHANDLUNG HÄMATOLOGISCHER MALIGNOME MIT 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZ YL)AMINO)ISOINDOLINE-1,3-DION

Status

Granted/Registered

Protection Type

European Patent

(AT-) Application Number

2020807558

EP Publication Number

4048278

E-Number

1626441

Language

PCT Number

US20056408

Publication Date

31.08.2022 A

01.11.2023 B1

Registration Date

01.11.2023

AT Publication Date

15.11.2023

Application Date

20.10.2020

Registration Number

Priorities

21.10.2019

201962924028 P

IPC

A61K 31/5377 20060101AFI20210430BHEP

Maximum Duration of Protection

20.10.2040

Owner

Celgene Corporation86 Morris Avenue Summit, NJ 07901US

Representative

Haffner und Keschmann Patentanwälte GmbHSchottengasse 3a1010 WienAT

Inventor

ANTON, Maria Soraya, Carrancioc/o Signal Pharmaceuticals, LLC 10300 Campus Point Drive, Suite 100 San Diego, CA 92121US

BUCHHOLZ, Tonia J.c/o Celgene Corporation 1500 Owens Street, Suite 600 San Francisco, CA 94185US

KASIBHATLA, Shailajac/o Signal Pharmaceuticals, LLC 10300 Campus Point Drive, Suite 100 San Diego, CA 92121US

LOPEZ-GIRONA, Antoniac/o Signal Pharmaceuticals, LLC 10300 Campus Point Drive, Suite 100 San Diego, CA 92121US

NARLA, Rama, Krishnac/o Signal Pharmaceuticals, LLC 10300 Campus Point Drive, Suite 100 San Diego, CA 92121US

POURDEHNAD, Michaelc/o Celgene Corporation 1500 Owens Street, Suite 600 San Francisco, CA 94185US

Information about Fees